A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1

Current Cancer Drug Targets

Volumn 9, Issue 3, 2009, Pages 354-365

  Stordal, Britta ^a,b   Davey, Ross ^b  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

BRCA1; Cisplatin; Genetically modified cell lines; Paclitaxel; Resistance; Sensitivity

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIHYDRODIOL DEHYDROGENASE; EPIRUBICIN; FLUOROURACIL; GLYCOPROTEIN P; PACLITAXEL;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CELL VIABILITY; CROSS ALLERGY; CROSS RESISTANCE; CYTOTOXICITY; DNA MODIFICATION; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG CANCER; NONHUMAN; OVARY CANCER; OVARY CARCINOMA;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; CELL LINE, TUMOR; CISPLATIN; FEMALE; GENES, BRCA1; HUMANS; NEOPLASMS; OXIDOREDUCTASES; P-GLYCOPROTEIN; PACLITAXEL; PHENOTYPE; TREATMENT OUTCOME;

EID: 65649146783     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909788166592     Document Type: Article

References (97)

1. Stordal, B.; Pavlakis, N.; Davey, R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 2007, 33, 688-703. (Pubitemid 350089290)
2. Kartalou, M.; Essigmann, J. M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478, 23-43. (Pubitemid 32530848)
3. Parekh, H.; Wiesen, K.; Simpkins, H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem. Pharmacol. 1997, 53, 461-470. (Pubitemid 27149538)
4. Orr, G. A.; Verdier-Pinard, P.; McDaid, H.; Horwitz, S. B. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22, 7280-7295. (Pubitemid 37487160)
5. Owatari, S.; Akune, S.; Komatsu, M.; Ikeda, R.; Firth, S. D.; Che, X. F.; Yamamoto, M.; Tsujikawa, K.; Kitazono, M.; Ishizawa, T.; Takeuchi, T.; Aikou, T.; Mercer, J. F.; Akiyama, S.; Furukawa, T. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007, 67, 4860-4868.
6. Komatsu, M.; Sumizawa, T.; Mutoh, M.; Chen, Z. S.; Terada, K.; Furukawa, T.; Yang, X. L.; Gao, H.; Miura, N.; Sugiyama, T.; Akiyama, S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 2000, 60, 1312-1316. (Pubitemid 30152000)
7. Chang, I. Y.; Kim, M. H.; Kim, H. B.; Lee, D. Y.; Kim, S. H.; Kim, H. Y.; You, H. J. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem. Biophys. Res. Commun. 2005, 327, 225-233. (Pubitemid 40051375)
8. Ban, N.; Takahashi, Y.; Takayama, T.; Kura, T.; Katahira, T.; Sakamaki, S.; Niitsu, Y. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 1996, 56, 3577-3582. (Pubitemid 26251655)
9. Li, D.; Jang, S. H.; Kim, J.; Wientjes, M. G.; Au, J. L. Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm. Res. 2003, 20, 45-50. (Pubitemid 36152916)
10. Transfection Guide. 1998, Promega Corportaion.
11. Wang, Y.; Huang, S. Adenovirus technology for gene manipulation and functional studies. Drug Discov. Today 2000, 5, 10-16. (Pubitemid 30069654)
12. Nesterova, M.; Cho-Chung, Y. S. Killing the messenger: antisense DNA and siRNA. Curr. Drug Targets 2004, 5, 683-689. (Pubitemid 39600007)
13. Kobayashi, H.; Takemura, Y.; Miyachi, H.; Ogawa, T. Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin. Invest. New Drugs 1991, 9, 313-319.
14. Scherr, M.; Morgan, M. A.; Eder, M. Gene silencing mediated by small interfering RNAs in mammalian cells. Curr. Med. Chem. 2003, 10, 245-256. (Pubitemid 36131657)
15. Mak, T. W.; Penninger, J. M.; Ohashi, P. S. Knockout mice: a paradigm shift in modern immunology. Nat. Rev. Immunol. 2001, 1, 11-19. (Pubitemid 33741971)
16. Kawai, H.; Kiura, K.; Tabata, M.; Yoshino, T.; Takata, I.; Hiraki, A.; Chikamori, K.; Ueoka, H.; Tanimoto, M.; Harada, M. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 2002, 35, 305-314. (Pubitemid 34158665)
17. Kuroda, H.; Sugimoto, T.; Ueda, K.; Tsuchida, S.; Horii, Y.; Inazawa, J.; Sato, K.; Sawada, T. Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy. Int. J. Cancer 1991, 47, 732-737.
18. Tassone, P.; Tagliaferri, P.; Perricelli, A.; Blotta, S.; Quaresima, B.; Martelli, M. L.; Goel, A.; Barbieri, V.; Costanzo, F.; Boland, C. R.; Venuta, S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 2003, 88, 1285-1291. (Pubitemid 36606348)
19. Quinn, J. E.; Kennedy, R. D.; Mullan, P. B.; Gilmore, P. M.; Carty, M.; Johnston, P. G.; Harkin, D. P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003, 63, 6221-6228. (Pubitemid 37255167)
20. Deng, H. B.; Adikari, M.; Parekh, H. K.; Simpkins, H. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother. Pharmacol. 2004, 54, 301-307. (Pubitemid 39304424)
21. Schmidt, M.; Hovelmann, S.; Beckers, T. L. A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis. Br. J. Cancer 2002, 87, 924-932. (Pubitemid 35252971)
22. Cui, H.; Darmanin, S.; Natsuisaka, M.; Kondo, T.; Asaka, M.; Shindoh, M.; Higashino, F.; Hamuro, J.; Okada, F.; Kobayashi, M.; Nakagawa, K.; Koide, H.; Kobayashi, M. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res. 2007, 67, 3345-3355. (Pubitemid 46724874)
23. Smith, V.; Hobbs, S.; Court, W.; Eccles, S.; Workman, P.; Kelland, L. R. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res. 2002, 22, 1993-1999.
24. Fan, J.; Banerjee, D.; Stambrook, P. J.; Bertino, J. R. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras. Biochem. Pharmacol. 1997, 53, 1203-1209. (Pubitemid 27224267)
25. Matta, H.; Eby, M. T.; Gazdar, A. F.; Chaudhary, P. M. Role of MRIT/cFLIP in protection against chemotherapy-induced apoptosis. Cancer Biol. Ther. 2002, 1, 652-660.
26. Vasey, P. A.; Jones, N. A.; Jenkins, S.; Dive, C.; Brown, R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol. 1996, 50, 1536-1540. (Pubitemid 26425109)
27. Ohmori, T.; Arteaga, C. L. Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP): potential role in CDDP-mediated cytotoxicity. Cell Growth Differ. 1998, 9, 345-353. (Pubitemid 28345888)
28. Osaki, S.; Nakanishi, Y.; Takayama, K.; Pei, X. H.; Ueno, H.; Hara, N. Transfer of IkappaBalpha gene increase the sensitivity of paclitaxel mediated with caspase 3 activation in human lung cancer cell. J. Exp. Clin. Cancer Res. 2003, 22, 69-75. (Pubitemid 36396660)
29. Mullan, P. B.; Quinn, J. E.; Gilmore, P. M.; McWilliams, S.; Andrews, H.; Gervin, C.; McCabe, N.; McKenna, S.; White, P.; Song, Y. H.; Maheswaran, S.; Liu, E.; Haber, D. A.; Johnston, P. G.; Harkin, D. P. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001, 20, 6123-6131. (Pubitemid 32964424)
30. Russo, A. J.; Magro, P. G.; Hu, Z.; Li, W. W.; Peters, R.; Mandola, J.; Banerjee, D.; Bertino, J. R. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Res. 2006, 66, 7253-7260. (Pubitemid 44197706)
31. Chen, S. Z.; Jiang, M.; Zhen, Y. S. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemother. Pharmacol. 2005, 56, 212-220. (Pubitemid 40884277)
32. Haber, M.; Bordow, S. B.; Gilbert, J.; Madafiglio, J.; Kavallaris, M.; Marshall, G. M.; Mechetner, E. B.; Fruehauf, J. P.; Tee, L.; Cohn, S. L.; Salwen, H.; Schmidt, M. L.; Norris, M. D. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene 1999, 18, 2777-2782. (Pubitemid 29237667)
33. Lafarge, S.; Sylvain, V.; Ferrara, M.; Bignon, Y. J. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001, 20, 6597-6606. (Pubitemid 32980286)
34. Ciardiello, F.; Caputo, R.; Pomatico, G.; De Laurentiis, M.; De Placido, S.; Bianco, A. R.; Tortora, G. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int. J. Cancer 2000, 85, 710-715. (Pubitemid 30080486)
35. Zaffaroni, N.; Pennati, M.; Colella, G.; Perego, P.; Supino, R.; Gatti, L.; Pilotti, S.; Zunino, F.; Daidone, M. G. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol. Life Sci. 2002, 59, 1406-1412.
36. Dodier, P.; Piche, A. Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells. Gynecol. Oncol. 2006, 100, 254-263. (Pubitemid 43075258)
37. Aigner, A.; Hsieh, S. S.; Malerczyk, C.; Czubayko, F. Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. Toxicology 2000, 144, 221-228. (Pubitemid 30201640)
38. Duan, Z.; Duan, Y.; Lamendola, D. E.; Yusuf, R. Z.; Naeem, R.; Penson, R. T.; Seiden, M. V. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin- resistant human cancer cell lines. Clin. Cancer Res. 2003, 9, 2778-2785. (Pubitemid 36842124)
39. Cole, S. P.; Sparks, K. E.; Fraser, K.; Loe, D. W.; Grant, C. E.; Wilson, G. M.; Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54, 5902-5910. (Pubitemid 24375226)
40. Duan, Z.; Lamendola, D. E.; Yusuf, R. Z.; Penson, R. T.; Preffer, F. I.; Seiden, M. V. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res. 2002, 22, 1933-1941.
41. Xing, D.; Orsulic, S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res. 2006, 66, 8949-8953. (Pubitemid 44521109)
42. Trenz, K.; Lugowski, S.; Jahrsdorfer, U.; Jainta, S.; Vogel, W.; Speit, G. Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics. Mutat. Res. 2003, 544, 279-288. (Pubitemid 37487669)
43. Andriani, F.; Perego, P.; Carenini, N.; Sozzi, G.; Roz, L. Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer. Neoplasia 2006, 8, 9-17.
44. Fan, S.; Chang, J. K.; Smith, M.L.; Duba, D.; Fornace, A. J., Jr.; O'Connor, P. M. Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 1997, 14, 2127-2136. (Pubitemid 27248224)
45. Osaki, S.; Nakanishi, Y.; Takayama, K.; Pei, X. H.; Ueno, H.; Hara, N. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. Cancer Gene Ther. 2000, 7, 300-307. (Pubitemid 30194566)
46. Minagawa, Y.; Kigawa, J.; Itamochi, H.; Kanamori, Y.; Shimada, M.; Takahashi, M.; Terakawa, N. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Jpn J. Cancer Res. 1999, 90, 1373-1379. (Pubitemid 30032077)
47. Hawkins, D. S.; Demers, G. W.; Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996, 56, 892-898. (Pubitemid 26055483)
48. Tsaryk, R.; Fabian, K.; Thacker, J.; Kaina, B. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett. 2006, 239, 305-313. (Pubitemid 43977859)
49. Zaffaroni, N.; Daidone, M. G. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Updat. 2002, 5, 65-72.
50. Kojima, H.; Iida, M.; Yaguchi, Y.; Suzuki, R.; Hayashi, N.; Moriyama, H.; Manome, Y. Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 682-685. (Pubitemid 43927048)
51. Pennati, M.; Colella, G.; Folini, M.; Citti, L.; Daidone, M. G.; Zaffaroni, N. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest. 2002, 109, 285-286. (Pubitemid 34083749)
52. Chen, Y. J.; Yuan, C. C.; Chow, K. C.; Wang, P. H.; Lai, C. R.; Yen, M. S.; Wang, L. S. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol. Oncol. 2005, 97, 110-117. (Pubitemid 40403682)
53. Chow, K. C.; Lu, M. P.; Wu, M. T. Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma. J. Dermatol. Sci. 2006, 41, 205-212. (Pubitemid 43246721)
54. Liang, Y.; Meleady, P.; Cleary, I.; McDonnell, S.; Connolly, L.; Clynes, M. Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur. J. Cancer 2001, 37, 1041-1052. (Pubitemid 32397691)
55. Burns, B. S.; Edin, M. L.; Lester, G. E.; Tuttle, H. G.; Wall, M. E.; Wani, M. C.; Bos, G. D. Selective drug resistant human osteosarcoma cell lines. Clin. Orthop. Relat. Res. 2001, 259-267. (Pubitemid 32126171)
56. Yamamoto, K.; Kikuchi, Y.; Kudoh, K.; Nagata, I. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.[erratum appears in J Cancer Res Clin Oncol 2001 Feb;127(2):142]. J. Cancer Res. Clin. Oncol. 2000, 126, 168-172. (Pubitemid 32449085)
57. Takeuchi, T.; Yoshitomi, S.; Higuchi, T.; Ikemoto, K.; Niwa, S.; Ebihara, T.; Katoh, M.; Yokoi, T.; Asahi, S. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm. Res. 2006, 23, 1460-1472. (Pubitemid 43993809)
58. Yang, H.; He, L.; Kruk, P.; Nicosia, S. V.; Cheng, J. Q. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int. J. Cancer 2006, 119, 2304-2312. (Pubitemid 44546949)
59. Chen, J.; Xiong, J.; Liu, H.; Chernenko, G.; Tang, S. C. Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line. Oncogene 2002, 21, 7050-7059. (Pubitemid 35252979)
60. Liu, J. R.; Fletcher, B.; Page, C.; Hu, C.; Nunez, G.; Baker, V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol. 1998, 70, 398-403. (Pubitemid 28473641)
61. Eichele, K.; Ramer, R.; Hinz, B. Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene 2008, 27, 3032-3044.
62. Ma, Y.; Freeman, S. N.; Cress, W. D. E2F4 deficiency promotes drug-induced apoptosis. Cancer Biol. Ther. 2004, 3, 1262-1269. (Pubitemid 41350963)
63. Chien, J.; Aletti, G.; Baldi, A.; Catalano, V.; Muretto, P.; Keeney, G. L.; Kalli, K. R.; Staub, J.; Ehrmann, M.; Cliby, W. A.; Lee, Y. K.; Bible, K. C.; Hartmann, L. C.; Kaufmann, S. H.; Shridhar, V. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J. Clin. Invest. 2006, 116, 1994-2004. (Pubitemid 44033323)
64. Grim, J.; D'Amico, A.; Frizelle, S.; Zhou, J.; Kratzke, R. A.; Curiel, D. T. Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel. Clin. Cancer Res. 1997, 3, 2415-2423. (Pubitemid 28133163)
65. Masuyama, H.; Nakatsukasa, H.; Takamoto, N.; Hiramatsu, Y. Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol. Pharmacol. 2007, 72, 1045-1053. (Pubitemid 47481427)
66. Tsuruta, Y.; Mandai, M.; Konishi, I.; Kuroda, H.; Kusakari, T.; Yura, Y.; Hamid, A. A.; Tamura, I.; Kariya, M.; Fujii, S. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. Eur. J. Cancer 2001, 37, 531-541. (Pubitemid 32232119)
67. Kim, R.; Minami, K.; Nishimoto, N.; Toge, T. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int. J. Oncol. 2001, 18, 363-367.
68. Kim, R.; Emi, M.; Tanabe, K.; Toge, T. Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 2004, 101, 2177-2186. (Pubitemid 39458671)
69. Kim, R.; Tanabe, K.; Uchida, Y.; Emi, M.; Toge, T. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. Int. J. Mol. Med. 2003, 11, 799-804.
70. Warmann, S. W.; Frank, H.; Heitmann, H.; Ruck, P.; Herberts, T.; Seitz, G.; Fuchs, J. Bcl-2 gene silencing in pediatric epithelial liver tumors. J. Surg. Res. 2008, 144, 43-48. (Pubitemid 350234956)
71. Gan, P. P.; Pasquier, E.; Kavallaris, M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 2007, 67, 9356-9363. (Pubitemid 47535925)
72. Brader, K. R.; Wolf, J. K.; Hung, M. C.; Yu, D.; Crispens, M. A.; van Golen, K. L.; Price, J. E. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin. Cancer Res. 1997, 3, 2017-2024. (Pubitemid 27505128)
73. Bai, L.; Zhu, R.; Chen, Z.; Gao, L.; Zhang, X.; Wang, X.; Bai, C. Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells. Biochem. Pharmacol. 2006, 71, 1265-1271. (Pubitemid 43357907)
74. Kim, R.; Ohi, Y.; Inoue, H.; Aogi, K.; Toge, T. Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis. Anticancer Res. 1999, 19, 1779-1783. (Pubitemid 29392737)
75. Zhang, X.; Ling, M. T.; Wong, Y. C.; Wang, X. Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis. Cancer Sci. 2007, 98, 308-314. (Pubitemid 46195599)
76. Hellawell, G. O.; Ferguson, D. J.; Brewster, S. F.; Macaulay, V. M. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int. 2003, 91, 271-277. (Pubitemid 36232849)
77. Shridhar, V.; Bible, K. C.; Staub, J.; Avula, R.; Lee, Y. K.; Kalli, K.; Huang, H.; Hartmann, L. C.; Kaufmann, S. H.; Smith, D. I. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 2001, 61, 4258-4265. (Pubitemid 32720997)
78. Paffhausen, T.; Schwab, M.; Westermann, F. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett. 2007, 250, 17-24. (Pubitemid 46483842)
79. Yang, C. C.; Hsu, C. P.; Yang, S. D. Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells. Clin. Cancer Res. 2000, 6, 1024-1030. (Pubitemid 30159363)
80. Wang, H.; Qian, H.; Yu, J.; Zhang, X.; Zhang, L.; Fu, M.; Liang, X.; Zhan, Q.; Lin, C. Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol. Ther. 2006, 5, 380-385.
81. Iwado, E.; Daido, S.; Kondo, Y.; Kondo, S. Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo. Int. J. Oncol. 2007, 31, 1087-1095.
82. Abou El Hassan, M. A.; Mastenbroek, D. C.; Gerritsen, W. R.; Giaccone, G.; Kruyt, F. A. Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. Br. J. Cancer 2004, 91, 171-177. (Pubitemid 39022568)
83. Moussa, O.; Riker, J. M.; Klein, J.; Fraig, M.; Halushka, P. V.; Watson, D. K. Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 2008, 27, 55-62.
84. Samimi, G.; Safaei, R.; Katano, K.; Holzer, A. K.; Rochdi, M.; Tomioka, M.; Goodman, M.; Howell, S. B. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 2004, 10, 4661-4669. (Pubitemid 38955516)
85. Mullan, P. B.; Gorski, J. J.; Harkin, D. P. BRCA1 - a good predictive marker of drug sensitivity in breast cancer treatment? Biochim. Biophys. Acta 2006, 1766, 205-216. (Pubitemid 46321455)
86. Husain, A.; He, G.; Venkatraman, E. S.; Spriggs, D. R. BRCA1 upregulation is associated with repair-mediated resistance to cis- diamminedichloroplatinum(II). Cancer Res. 1998, 58, 1120-1123. (Pubitemid 28183195)
87. Bhattacharyya, A.; Ear, U. S.; Koller, B. H.; Weichselbaum, R. R.; Bishop, D. K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 2000, 275, 23899-23903. (Pubitemid 30624678)
88. Zhou, C.; Huang, P.; Liu, J. The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells. Biochem. Biophys. Res. Commun. 2005, 336, 952-960. (Pubitemid 41338360)
89. Chabalier, C.; Lamare, C.; Racca, C.; Privat, M.; Valette, A.; Larminat, F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006, 5, 1001-1007.
90. Dieras, V.; Bougnoux, P.; Petit, T.; Chollet, P.; Beuzeboc, P.; Borel, C.; Husseini, F.; Goupil, A.; Kerbrat, P.; Misset, J. L.; Bensmaine, M. A.; Tabah-Fisch, I.; Pouillart, P. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Ann. Oncol. 2002, 13, 258-266. (Pubitemid 34704978)
91. Aida, H.; Takakuwa, K.; Nagata, H.; Tsuneki, I.; Takano, M.; Tsuji, S.; Takahashi, T.; Sonoda, T.; Hatae, M.; Takahashi, K.; Hasegawa, K.; Mizunuma, H.; Toyoda, N.; Kamata, H.; Torii, Y.; Saito, N.; Tanaka, K.; Yakushiji, M.; Araki, T.; Tanaka, K. Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clin. Cancer Res. 1998, 4, 235-240. (Pubitemid 28062902)
92. Ben David, Y.; Chetrit, A.; Hirsh-Yechezkel, G.; Friedman, E.; Beck, B. D.; Beller, U.; Ben Baruch, G.; Fishman, A.; Levavi, H.; Lubin, F.; Menczer, J.; Piura, B.; Struewing, J. P.; Modan, B. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J. Clin. Oncol. 2002, 20, 463-466. (Pubitemid 34072530)
93. Boyd, J.; Sonoda, Y.; Federici, M. G.; Bogomolniy, F.; Rhei, E.; Maresco, D. L.; Saigo, P. E.; Almadrones, L. A.; Barakat, R. R.; Brown, C. L.; Chi, D. S.; Curtin, J. P.; Poynor, E. A.; Hoskins, W. J. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000, 283, 2260-2265. (Pubitemid 30246777)
94. Taron, M.; Rosell, R.; Felip, E.; Mendez, P.; Souglakos, J.; Ronco, M. S.; Queralt, C.; Majo, J.; Sanchez, J. M.; Sanchez, J. J.; Maestre, J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 2004, 13, 2443-2449. (Pubitemid 39377848)
95. Kurebayashi, J.; Yamamoto, Y.; Kurosumi, M.; Okubo, S.; Nomura, T.; Tanaka, K.; Sonoo, H. Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res. 2006, 26, 695-701. (Pubitemid 43206036)
96. Lambie, H.; Miremadi, A.; Pinder, S. E.; Bell, J. A.; Wencyk, P.; Paish, E. C.; Macmillan, R. D.; Ellis, I. O. Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J. Pathol. 2003, 200, 207-213. (Pubitemid 36748029)
97. Yang, Q.; Sakurai, T.; Mori, I.; Yoshimura, G.; Nakamura, M.; Nakamura, Y.; Suzuma, T.; Tamaki, T.; Umemura, T.; Kakudo, K. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 2001, 92, 54-60. (Pubitemid 32623040)